oral semaglutide weight loss real-world study For patients with #obesity, semaglutide, a glucagon-like peptide-1 receptor agonist, is approved for management as a once-weekly subcutaneous injection. In a previous trial, at a dose of 50 mg A Real-World Study of the

Chemical Name/Structure

Clinical trials found about 13.6% average body weight reduction with the oral form and about 14.9% with the injection, though the trials weren't designed for a direct comparison

Variants in the GLP1R gene (such as rs6923761) and GIPR gene (such as rs1800437) can affect receptor sensitivity and downstream signaling, potentially favoring one medication over another for your metabolism

This means it helps slow down how fast your stomach empties, so you feel full for longer after meals

Clinicians and patients should therefore maintain a low threshold for investigation, particularly in those with identifiable risk factors